SNSW(SH:688117) Zhi Tong Cai Jing·2026-01-15 11:32Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 152 million to 190 million yuan in 2025, representing a year-on-year increase of 204.42% to 280.53% [1] Group 1: Financial Performance - The projected net profit for 2025 indicates significant growth compared to the previous year, highlighting the company's strong financial trajectory [1] - The anticipated profit growth is driven by increased demand for the company's peptide raw material business, which has seen a steady rise in orders [1] Group 2: Strategic Initiatives - The company is focused on executing its annual business strategy while simultaneously expanding its domestic and international markets [1] - Ongoing capacity expansion efforts are expected to contribute to the overall performance improvement [1] Group 3: Market Position - The company's performance enhancement is expected to strengthen its global competitiveness in the peptide pharmaceutical market [1]